SYHA1805 / CSPC Pharma - LARVOL DELTA

First-in-Human Dose Selection, Pharmacokinetics Prediction, and Clinical Validation of SYHA1805, a Novel FXR Agonist, Using Allometric Scaling and PBPK Modeling. (PubMed, Pharmaceutics) - P1 | "The model simulations were subsequently validated by clinical trial data from a single ascending dose (SAD) study (CTR20202354). These findings establish a robust pharmacokinetic foundation for the continued clinical advancement of SYHA1805."

First-in-human • Journal • P1 data • PK/PD data • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis

A Study of SYHA1805 in Healthy Subjects (clinicaltrials.gov) - P1; N=36; Not yet recruiting; Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

New P1 trial